Category: 3. Business

  • Here’s what bitcoin and U.S. Treasurys have in common right now

    Here’s what bitcoin and U.S. Treasurys have in common right now

    By Charlie Garcia

    Charlie Garcia responds to readers concerned about weakening demand for both cryptocurrency and U.S. government debt

    Editor’s note: Columnist Charlie Garcia shares select emails from his virtual mailbag each week.

    Dear Charlie,

    I just finished reading your latest article in MarketWatch re: “Bitcoin isn’t dead – it’s having an IPO moment.”

    For someone who missed out on bitcoin (BTCUSD) in its initial “IPO,” how can I best get into it now and secure my children’s future?

    Thanks,

    Ezra

    Dear Ezra,

    I’m not a financial adviser, so I can’t tell you specifically what to do with your family’s money. But I can share the general framework I think about.

    First, let’s kill the idea that you “missed” anything. Missing the “IPO” means you didn’t buy at $1. You also didn’t buy at $1,000, $10,000 or $50,000.

    If bitcoin trades where I think it will 20 years from now, the difference between buying at $20,000 and buying at $85,000 will look like a rounding error.

    The real question isn’t “Did I miss it?” The question is: “What role should this play in securing my family’s future?”

    Read: ‘My retirement is completely in bitcoin’: Why don’t more people do what I do?

    The boring truth: Your kids’ future gets secured the same way your grandfather’s did: Spend less than you make; max out retirement accounts; own stuff that pays you to own it; and don’t do stupid things with debt. Bitcoin doesn’t replace this. Nothing replaces this.

    Bitcoin is the moonshot: It’s 10% of your portfolio, max, and only if you can watch it crater 50% without selling in a panic and buying a Peloton. It’s what you put there because IF this thing works, that slice changes everything.

    Practically: Don’t jump from zero to 10% overnight. Start at 2%-3%. Live with it six months. When it drops 20%, notice whether you’re checking the price every three minutes. If you are, you sized the position wrong.

    Dollar-cost average into the investment over 12-18 months. You’re building a position, not timing bottoms. Think 20 years minimum. Your kids will inherit a different world than this one – plan accordingly.

    What this isn’t: Betting the mortgage. Replacing college funds. Getting rich quick. If you want your kids’ future secured, do the unglamorous work: Eliminate debt; own productive assets that generate income; teach them money isn’t magic.

    Charlie

    P.S.: The real risk isn’t buying too late. It’s watching your money instead of watching your kids grow up. One of those is actually irreplaceable.

    Dear Charlie,

    The concern expressed in your article – “America’s ‘sugar daddy’ just went broke – and you’re stuck with the bill” – might be legitimate if the yen (USDJPY) were the world’s reserve currency.

    Despite all the arguments to the contrary, the U.S. does not depend on the sale of Treasurys to pay its bills. Treasurys are provided by the U.S. government as a safe place to earn a return on cash (which is pushed out into the economy by the Fed), and this is all about “Japanese investors can make actual money at home.”Anyone who still thinks the U.S. should retire its “debt” by shutting down the Treasury market has no clue how the U.S. economy actually works.

    Mike

    Dear Mike,

    Fair challenge, but three things:

    1. Reserve-currency status gets revoked when abused: Sterling was the reserve currency until the U.K. acted like printing it had no consequences. The U.S. is running the same playbook: $2 trillion deficits in a “strong” economy, 120% debt-to-GDP, Fed monetizing 40% of COVID issuance. History says this ends badly.

    2. Japan matters because it was the marginal buyer keeping America’s bond market liquid: When the world’s largest creditor ($1.1 trillion in Treasurys) can earn 1% at home instead of 4.5% here with currency risk, that’s a liquidity event. The carry trade was the lubricant keeping global asset prices inflated. When it reverses, everything reprices.

    3. Yes, the U.S. can print dollars, but every dollar created dilutes every existing dollar DXY: That’s not funding, that’s confiscating purchasing power. Treasuries only work if they beat inflation. At 4.5% yields against 6%-8% real inflation, you’re losing wealth annually. Smart money moves to what government can’t dilute.

    The question isn’t “Can they print?” It’s “What happens to your wealth when they do?”

    Charlie

    P.S.: Every reserve currency failed the same way. This is pattern, not theory.

    Dear Charlie,

    I just wanted to point out that if Japan is selling U.S. Treasury bonds, someone is buying them. If the buyer is the U.S. government, great – they’re reducing their debt. If it’s anyone else, it’s irrelevant to the U.S.To use your bar analogy: Japan has the receipt – they picked up the tab. When someone else buys that receipt from Japan, they can claim they paid the tab. But the bar that issued the receipt is unaffected by this transaction.I’d agree with your premise if Japan leaves a void that no one else has an interest in filling. Which seems improbable to me, at least in the short term.

    Ben

    Dear Ben,

    Great question, and you’re technically right but practically wrong. Let me explain why:

    You’re correct that secondary market transactions don’t directly affect the Treasury’s balance sheet. When Japan sells to someone else, the U.S. doesn’t care who holds the receipt. But here’s what you’re missing:

    1. Price matters: When Japan sells Treasurys, yields spike because supply overwhelms demand at current rates. You’re right that someone will buy them, but at what price? When yields jump to 5% from 4%, that’s not “irrelevant” to the U.S. America rolls $9 trillion in debt annually. A 1% increase costs the U.S. $90 billion a year.

    2. The “void” is already here: Japan held Treasurys because it had no choice. Now Japanese can get positive real returns domestically. China’s been selling Treasurys for two years. Who’s filling that void? The Fed (money printing) and leveraged buyers (unstable). Primary dealers are choking on inventory they can’t move.

    3. The bar needs to keep issuing new receipts: If word spreads that receipts aren’t worth as much, the bar has to offer bigger discounts to get people to take new ones. That directly affects the bar’s cost of operation.

    The real issue isn’t Japan selling existing bonds; it’s Japan not buying new ones. When your biggest customer stops showing up and you need to keep selling product, you either drop prices or find new customers.

    We’re doing both, and neither is free.

    Thanks for the sharp question. You can be technically correct and still end up broke.

    Charlie

    P.S.: Watch the next 10-year U.S. Treasury BX:TMUBMUSD10Y auction. If bid-to-cover ratios keep falling and yields keep rising, that’s your answer about whether this matters.

    Dear Charlie,

    To borrow from Mark Twain: “Reports of the death of the carry trade were greatly exaggerated… for decades.”

    Like the yogurt I find in the back of the break-room refrigerator, it’s past the use-by date. I’ve been conducting experiments with how much wiggle room there is on that date – about 35 days max if you skim the mold off the top.

    According to the article, the carry trade is past the point of human consumption. There’s clearly deleveraging happening.

    But here’s a possible constructive scenario: In a few months there will be a new Fed chair who will probably attempt to grow the U.S. out of these unsustainable fiscal deficits. If that works, foreign capital flows back to the U.S., the dollar resurges, and longer rates stay subdued.

    Right?

    Margaret

    Dear Margaret,

    The yogurt analogy is perfect, except you’re assuming the expiration date on the container is accurate.

    With the carry trade, someone has changed the label three times already.

    Here’s the problem with your constructive scenario: “Growing out of deficits” requires that productivity grow faster than debt grows. The U.S. is adding $2 trillion in debt annually while GDP grows at 2%-3%.

    That’s not yogurt math, that’s compounding insolvency with an optimistic PowerPoint.

    The new Fed chair inherits an impossible mandate: keep rates low enough that the government doesn’t bankrupt itself on interest payments, but high enough that the dollar doesn’t collapse and inflation doesn’t rage.

    Pick one. You can’t have both. Japan just proved this. They tried to thread that needle for 30 years and the thread broke.

    Foreign capital will come to the U.S. for growth, but only if the returns are real. When Treasury yields are 4.5% and inflation is 6%-8%, that’s not investment, that’s a charitable donation.

    The smart foreign money is already rotating into hard assets. The dumb money will keep buying bonds until the yogurt kills them.

    Your scenario requires three miracles: a productivity explosion, fiscal discipline and central bankers who prioritize currency stability over political convenience. I’ll take the under on all three.

    Skimming fungus off expired financial products since 2008,

    Charlie

    P.S.: The carry trade isn’t dead, it just moved. Now it’s leveraged U.S. equity positions funded by – well, we’ll find out when that unwinds too.

    Charlie Garcia is founder and a managing partner of R360, a peer-to-peer organization for individuals and families with a net worth of $100 million or more. He holds bitcoin in his personal account.

    Agree? Disagree? Share your comments with Charlie Garcia at charlie@R360Global.com. Your letter may be published anonymously in the weekly “Dear Charlie” reader mailbag. By emailing your comments to Charlie Garcia, you agree to have them published on MarketWatch anonymously, or with your first name if you give permission.

    You understand and agree that Dow Jones & Co., the publisher of MarketWatch, may use your story, or versions of it, in all media and platforms, including via third parties.

    More from Charlie Garcia:

    (MORE TO FOLLOW) Dow Jones Newswires

    11-23-25 1530ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Hitting 100 Million RMB in One Night — What Chicjoc Got Right

    Hitting 100 Million RMB in One Night — What Chicjoc Got Right

    China’s Double 11 shopping period this year once again proved the scale of the country’s consumer market: online retail sales reached nearly 2.4 trillion yuan, or $337.69 billion, marking double-digit, year-over-year growth. While major platforms kept sales reports intentionally low-key, several breakout brands delivered performance that cut through the noise.

    Among them was Chicjoc. Its “Super Fashion Launch 2.0,” a global livestream co-created with Taobao Clothing, ran for 30 continuous hours and generated more than 100 million yuan in sales — a milestone that has quickly become part of Double 11 lore.

    More from WWD

    The achievement offered a counterargument to recent pessimism about China’s consumer sentiment. The market is indeed more complex and volatile than before, but enthusiasm for quality products remains robust and the country’s purchasing potential is far from exhausted. The real challenge for brands today is navigating the shift from “scale dividends” to “innovation dividends” — and capturing the momentum of this era.

    Since 2023, WWD China has been tracking the rise of a cohort of high-quality domestic brands. Chicjoc, one of the most internationally ambitious among them, came onto our radar in 2024. Over the past year it has rapidly expanded in global markets: its first U.S. boutique opening, a European debut in Paris, appearances at international fashion weeks, collaborations with overseas designers, and now a landmark livestream that has become a case study across the industry.

    Lynn Fu, chief executive officer of WWD China, attributes the brand’s breakthrough to its alignment with market timing, its global supply-and-retail footprint, and its investment in digital and operational capabilities. All of this, she noted, is rooted in a distinctly Chinese approach — one that prioritizes product excellence, brand credibility and a long-term moat of core competitiveness.

    Chicjoc’s livestream strategy has evolved into a hybrid runway-show-meets-content-studio format that targets global audiences with day-to-night styling and cinematic storytelling. The format not only expands its consumer reach but also strengthens the brand’s identity.

    The foundation for this year’s performance was laid in 2023. That season, Chicjoc introduced film-grade visuals, multi-camera transitions, and scenes recreating the intimacy of a designer atelier. Models showcased new collections while designers offered commentary on fabrics and craftsmanship — a format that underscored the brand’s “intellectual wardrobe” philosophy.

    The livestream generated 60 million yuan in sales, with fall-winter pieces averaging 6,000 yuan per unit. One item surpassed 10 million yuan in sales, three exceeded 5 million yuan, and 12 crossed the 1 million mark. It was an early indicator that runway-caliber livestreams would become a new competitive frontier on platforms like Taobao Clothing and Douyin.

    For Double 11 this year, Chicjoc and Taobao Clothing upgraded the concept. The 2.0 version preserved the high-fashion visual language while layering in richer storytelling and deeper interaction. Founder Wei Yujing appeared alongside industry figures such as designers Bonnetje and Freya Dalsjø, formerly of Maison Margiela and Balenciaga. Together with brand ambassadors, they wove discussions of creative philosophy, craftsmanship and aesthetics into the show.

    Bonnetje cofounders Anna Myntekær (left) and Yoko Maja Hansen (right).

    Segments ranged from international supermodel presentations to extensions of the brand’s Milan Fashion Week showcase, with invited guests sharing interpretations of “time” as a narrative theme. The result was a dialogue between fashion, culture and storytelling that heightened engagement and further cemented Chicjoc’s brand equity.

    When international designers travel thousands of miles to appear on a Chinese livestream, the visual contrast of Eastern and Western aesthetics is striking. But behind the scenes is Chicjoc’s larger ambition: to help shape a new global fashion map.

    In August 2024, the brand joined Taobao Clothing’s worldwide free-shipping initiative. Three months later, it opened its first U.S. boutique. Today it operates more than 40 retail locations globally. The combination of Taobao’s cross-border logistics and the brand’s overseas stores creates a frictionless “see now, buy now, receive now” loop for global consumers.

    Ahead of this year’s Milan Fashion Week, Chicjoc deepened its collaboration with a rising Copenhagen-based design duo through the WWD Select design incubation platform. During its Double 11 livestream, this partnership evolved from resource sharing to value creation. Founder-designer conversations explored the intersections of minimalism, sustainability and modern wardrobe design — signaling a shift toward globally resonant aesthetics.

    What gives Chicjoc the confidence to compete on an international stage? The brand’s strategy rests on three pillars: an expanding global retail network, an omnichannel understanding of consumer behavior, and the ability to create bestselling “super products” through an agile supply chain. The company, founded as a Taobao shop in 2013 and formalized as an e-commerce brand in 2015, combines digital-native instincts with disciplined product focus.

    The Chinese consumer landscape has also reshaped the brand’s trajectory. A new generation of shoppers has moved past firm loyalty to foreign luxury labels and beyond the race to chase the lowest price. They prioritize aesthetics, quality and “worth” — a value system that increasingly aligns with global standards of sustainable and rational consumption.

    This consumer environment offers three advantages:
    • A high-speed innovation lab, where robust supply chains turn global ideas into real products rapidly.
    • A value resonance zone, where demand for quality and aesthetics matches global conversations around sustainable fashion.
    • A creative ecosystem, where China’s manufacturing capabilities and market depth attract global talent and collaboration.

    Given this backdrop, Chicjoc’s 100 million yuan, 30-hour global livestream success is less a coincidence than a reflection of structural transformation. China’s fashion market has entered the era of “value innovation,” where brands win not by discounting but by storytelling, technology, global integration and emotional connection.

    As marketers increasingly move away from traffic-driven or discount-driven strategies, the essence of Double 11 is shifting. Shopping festivals are no longer battles of price cuts; they are stages for brand identity, creativity and cross-border cultural exchange.

    Chicjoc, positioned as a rising force in the women’s fashion market, has opted out of price wars and instead leaned into an international narrative — one that fuses Chinese design intelligence with global aesthetics.

    As China’s fashion industry transitions from “scale dividends” to “innovation dividends,” the rules of the game are being rewritten. Chicjoc’s performance marks not just a brand success, but a signal of how China’s fashion leaders will compete — and collaborate — on the world stage in the years ahead.

    Editor’s Note: China Insight is a monthly column from WWD’s sister publication WWD China looking at trends in that all-important market.

    Best of WWD

    Sign up for WWD’s Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

    Continue Reading

  • Bond Rally of 2025 Faces New Data Vacuum as Waiting Game Begins

    Bond Rally of 2025 Faces New Data Vacuum as Waiting Game Begins

    A pedestrians passes the US Treasury building in Washington, DC.

    The rally that powered the US bond market toward its best year since 2020 has now left investors in suspense to see whether Treasuries can hold their impressive gains.

    Most Read from Bloomberg

    US 10-year yields declined last week, sending the benchmark back toward 4% as spasms in stocks and crypto sparked demand for bonds. Fresh commentary from John Williams, the president of the Federal Reserve Bank of New York, added to the bid, reviving expectations for an interest-rate cut next month.

    Heading into the Thanksgiving holiday-shortened week, the benchmark Bloomberg Treasuries index is on track for a small gain in November after rising in eight of the prior 10 months. And yet, while the tone is still generally upbeat, the market is mired below October’s price highs and yields are range-bound.

    Absent a fresh bout of risk-off buying, and with no major economic data to speak of until after the Fed’s December meeting, that’s likely how things will stay for the foreseeable future, market watchers say.

    “For a meaningful rally, the market is going to need some hard data,” said Kathy Jones, chief fixed-income strategist at Charles Schwab.

    The $30 trillion US bond market has been confined to a trading band in recent weeks as a lack of clear signals on jobs and inflation — complicated in part by distortions from the recent government shutdown — divided Fed policymakers and made a third consecutive rate cut less of a sure thing.

    “Certainly there’s no catalyst for the 10-year to go below 4% again,” said Kevin Flanagan, head of fixed income strategy at WisdomTree. Across the yield curve, Treasuries are “stuck in the mud,” he added.

    The lack of conviction is showing up in a measure of bond market volatility. Market swings remain near historical lows after picking up from last month’s four-year low.

    Official US employment data for September was finally released on Thursday, but it revealed a mixed picture that did little to settle the debate about the central bank’s likely path. On Friday, though, odds for a December cut climbed back near 65% after New York Fed President Williams said he sees room to lower interest rates in the near term as the labor market softens.

    “A cut is more likely than not” in December, said Amar Reganti, fixed-income strategist at Hartford Funds. That said, he added, “inflation is above target and yes the labor market is weaker but that’s also a lagging indicator, so we don’t know how far it goes. You can make plausible arguments either way.”

    Continue Reading

  • Fei-Fei Li, the ‘Godmother of AI,’ Got Her Start As a Dry Cleaner

    Fei-Fei Li, the ‘Godmother of AI,’ Got Her Start As a Dry Cleaner

    Every influential scientist has an origin story — and the “Godmother of AI” is no different.

    Fei-Fei Li, a Stanford professor best known for her work on ImageNet, is now the founder of World Labs, a one-year-old AI startup that’s already valued at over $1 billion.

    Her start, however, was far more humble.

    Li immigrated to the United States from China at the age of 15 and helped her parents run a dry-cleaning business in Parsippany, New Jersey, to make ends meet.

    “We were not financially very well off at all. My parents were doing cashier jobs and I was doing Chinese restaurant jobs,” she told Bloomberg in a Q&A. “My family and I decided to run a little dry cleaner shop to make some money to survive.”

    Li said she likes to joke that she was the “CEO.” She ran the shop for seven years, from when she was 18 until the middle of her graduate studies.

    According to her LinkedIn profile, Li attended Princeton University for college, keeping her close to her parents’ shop. Later, while pursuing her Ph.D. at Caltech in California, she continued to run the business remotely.

    “I was the one who spoke English. So I took all the customer phone calls, I dealt with the billing, the inspections, all the business,” she said.

    The experience, she said, taught her the value of resilience — a principle that continues to guide her career.

    “As a scientist, you have to be resilient because science is a non-linear journey. Nobody has all the solutions. You have to go through such a challenge to find an answer. And as an immigrant, you learn to be resilient,” she said.

    At World Labs, Li has big ambitions. She is working on building world models. These are AI models that leverage spatial intelligence, which Li says is “the ability for AI to understand, perceive, reason and interact [with the world]. It comes from a continuation of visual intelligence.”

    A growing number of AI experts believe that world models are what will propel the AI revolution into its next phase. Some believe large-language models, which are trained on, as the name suggests, lanaguage, and which the leading products are now based, are limited.

    Li said ImageNet, a comprehensive training dataset of visual information, was a precursor to world models.

    At the core of Li’s research is the idea that visual information, a passive way of understanding the world, is a crucial foundation for real-world action, which remains one of the ultimate goals of some top AI builders, like Meta Chief AI Scientist Yann LeCun, who recently announced he would step down to launch his own world model startup.

    The through-line between Li’s research and her immigrant story is the same.

    “I was always a curious kid, and then my curiosity had an outlet, which was science — and that really grounded me,” she told Bloomberg. “I wasn’t curious about nightclubs or other things. I was an avid lover of science.”


    Continue Reading

  • Jim Cramer Says Home Depot Stock is Going to Struggle if Fed Doesn’t Cut Rates Next Month

    Jim Cramer Says Home Depot Stock is Going to Struggle if Fed Doesn’t Cut Rates Next Month

    The Home Depot, Inc. (NYSE:HD) is one of the stocks Jim Cramer recently offered insights on. Cramer said that the company’s performance is dependant on whether the Fed cuts rate during the next meeting or not, as he commented:

    “On Tuesday, we kicked things off with Home Depot, and that was an inauspicious start. The despot posted a tiny sales beat, but both its earnings and the same-store sales came in softer than expected, and the stock plunged 6% in response. Ouch. Worse, Home Depot cut its full-year forecast for both comparable sales growth and earnings. There’s a tough set of numbers, no way around it.

    A stock market chart. Photo by Arturo A on Pexels

    The Home Depot, Inc. (NYSE:HD) is a home improvement retailer that sells tools, building materials, and decor. It also provides installation and equipment rental services.

    While we acknowledge the potential of HD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • van den Beuken-Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070-90.e9.

    Google Scholar 

  • Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin. 2018;68(3):182–96.

    Google Scholar 

  • Zheng XQ, Wu YH, Huang JF, Wu AM. Neurophysiological mechanisms of cancer-induced bone pain. J Adv Res. 2022;35:117–27.

    Google Scholar 

  • Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101(3):797–855.

    Google Scholar 

  • Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol. 2023;41(4):914–30.

    Google Scholar 

  • Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114147.

    Google Scholar 

  • Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019;393(10180):1558–68.

    Google Scholar 

  • Pers YM, Soler-Rich R, Vadalà G, Ferreira R, Duflos C, Picot MC, et al. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Ann Rheum Dis. 2024;83(11):1572–83.

    Google Scholar 

  • Ai M, Hotham WE, Pattison LA, Ma Q, Henson FMD, Smith ESJ. Role of human mesenchymal stem cells and derived extracellular vesicles in reducing sensory neuron hyperexcitability and pain behaviors in murine osteoarthritis. Arthritis Rheumatol. 2023;75(3):352–63.

    Google Scholar 

  • Zhu C, Wang K, Chen Z, Han Y, Chen H, Li Q, et al. Antinociceptive effect of intrathecal injection of miR-9-5p modified mouse bone marrow mesenchymal stem cells on a mouse model of bone cancer pain. J Neuroinflammation. 2020;17(1):85.

    Google Scholar 

  • Allouh MZ, Rizvi SFA, Alamri A, Jimoh Y, Aouda S, Ouda ZH, et al. Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises. Stem Cell Res Ther. 2025;16(1):127.

    Google Scholar 

  • Al-Ghadban S, Bunnell BA. Adipose tissue-derived stem cells: immunomodulatory effects and therapeutic potential. Physiol (Bethesda). 2020;35(2):125–33.

    Google Scholar 

  • Chu DT, Phuong TNT, Tien NLB, Tran DK, Thanh VV, Quang TL, et al. An update on the progress of Isolation, Culture, Storage, and clinical application of human bone marrow mesenchymal Stem/Stromal cells. Int J Mol Sci. 2020;21(3):708.

    Google Scholar 

  • Zhao J, Wang J, Dang J, Zhu W, Chen Y, Zhang X, et al. A preclinical study—systemic evaluation of safety on mesenchymal stem cells derived from human gingiva tissue. Stem Cell Res Ther. 2019;10(1):165.

    Google Scholar 

  • Zhuo Y, Li WS, Lu W, Li X, Ge LT, Huang Y, et al. TGF-β1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson’s disease models and patients. Mil Med Res. 2024;11(1):48.

    Google Scholar 

  • Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.

    Google Scholar 

  • Deuse T, Stubbendorff M, Tang-Quan K, Phillips N, Kay MA, Eiermann T, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011;20(5):655–67.

    Google Scholar 

  • He X, Yang Y, Yao M, Yang L, Ao L, Hu X, et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1298–304.

    Google Scholar 

  • Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022;75:103789.

    Google Scholar 

  • Hashemian SMR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12(1):91.

    Google Scholar 

  • Kamen DL, Wallace C, Li Z, Wyatt M, Paulos C, Wei C, et al. Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Sci Med. 2022;9(1):e000704.

    Google Scholar 

  • Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436–9.

    Google Scholar 

  • Yao H, Huang R, Fu H, Lin R, Zhang Y, Feng Y, et al. Sequential infusion of mesenchymal stem cell for Graft-Versus-Host disease prevention in haploidentical hematopoietic stem cell transplantation: an Open-Label, multicenter, randomized controlled clinical trial. J Clin Oncol. 2025;43(17):1997–2006.

    Google Scholar 

  • Huang R, Chen T, Wang S, Wang J, Su Y, Liu J, et al. Mesenchymal stem cells for prophylaxis of chronic Graft-vs-Host disease after haploidentical hematopoietic stem cell transplant: an Open-Label randomized clinical trial. JAMA Oncol. 2024;10(2):220–6.

    Google Scholar 

  • Cotten CM, Fisher K, Malcolm W, Gustafson KE, Cheatham L, Marion A, et al. A pilot phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Stem Cells Transl Med. 2023;12(6):355–64.

    Google Scholar 

  • Gu J, Huang L, Zhang C, Wang Y, Zhang R, Tu Z, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11(1):43.

    Google Scholar 

  • Amanat M, Majmaa A, Zarrabi M, Nouri M, Akbari MG, Moaiedi AR, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther. 2021;12(1):439.

    Google Scholar 

  • Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018;16(1):57.

    Google Scholar 

  • Kabatas S, Civelek E, Boyalı O, Sezen GB, Ozdemir O, Bahar-Ozdemir Y, et al. Safety and efficiency of wharton’s jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: first results of a phase I study. World J Stem Cells. 2024;16(6):641–55.

    Google Scholar 

  • Kaplan N, Kabatas S, Civelek E, Savrunlu EC, Akkoc T, Boyalı O, et al. Multiroute administration of wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: a phase I safety and feasibility study. World J Stem Cells. 2025;17(5):101675.

    Google Scholar 

  • Chahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, et al. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. Stem Cells Transl Med. 2019;8(8):746–57.

    Google Scholar 

  • Yousefifard M, Nasirinezhad F, Shardi Manaheji H, Janzadeh A, Hosseini M, Keshavarz M. Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model. Stem Cell Res Ther. 2016;7:36.

    Google Scholar 

  • Sipp D, Turner L. Stem cells. U.S. regulation of stem cells as medical products. Science. 2012;338(6112):1296–7.

    Google Scholar 

  • Barczewska M, Maksymowicz S, Zdolińska-Malinowska I, Siwek T, Grudniak M. Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: an original study. Stem Cell Rev Rep. 2020;16(5):922–32.

    Google Scholar 

  • Jamali F, Aldughmi M, Atiani S, Al-Radaideh A, Dahbour S, Alhattab D, et al. Human umbilical Cord-Derived mesenchymal stem cells in the treatment of multiple sclerosis patients: phase I/II Dose-Finding clinical study. Cell Transpl. 2024;33:9636897241233045.

    Google Scholar 

  • Shen W, Hu XM, Liu YN, Han Y, Chen LP, Wang CC, et al. Cxcl12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J Neuroinflammation. 2014;11:75.

    Google Scholar 

  • Xu C, Wang Y, Ni C, Xu M, Yin C, He Q, et al. Histone modifications and Sp1 promote GPR160 expression in bone cancer pain within rodent models. EMBO Rep. 2024;25(12):5429.

    Google Scholar 

  • Jiao Y, Sun YT, Chen NF, Zhou LN, Guan X, Wang JY, et al. Human umbilical cord-derived mesenchymal stem cells promote repair of neonatal brain injury caused by hypoxia/ischemia in rats. Neural Regen Res. 2022;17(11):2518–25.

    Google Scholar 

  • Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.

    Google Scholar 

  • Renesme L, Cobey KD, Lalu MM, Bubela T, Chinnadurai R, De Vos J, et al. Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics. Cytotherapy. 2025;27(2):146–68.

    Google Scholar 

  • Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55–63.

    Google Scholar 

  • Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77–88.

    Google Scholar 

  • Ding Z, Liang X, Wang J, Song Z, Guo Q, Schäfer MKE, et al. Inhibition of spinal ferroptosis-like cell death alleviates hyperalgesia and spontaneous pain in a mouse model of bone cancer pain. Redox Biol. 2023;62:102700.

    Google Scholar 

  • Vrinten DH, Hamers FFT. CatWalk automated quantitative gait analysis as a novel method to assess mechanical allodynia in the rat; a comparison with von Frey testing. Pain. 2003;102(1–2):203–9.

    Google Scholar 

  • Peirs C, Williams SPG, Zhao X, Walsh CE, Gedeon JY, Cagle NE, et al. Dorsal horn circuits for persistent mechanical pain. Neuron. 2015;87(4):797–812.

    Google Scholar 

  • Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148–54.

    Google Scholar 

  • Teng Y, Zhang Y, Yue S, Chen H, Qu Y, Wei H, et al. Intrathecal injection of bone marrow stromal cells attenuates neuropathic pain via inhibition of P2X4R in spinal cord microglia. J Neuroinflammation. 2019;16:271.

    Google Scholar 

  • Xu R, Ni B, Wang L, Shan J, Pan L, He Y, et al. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure. Stem Cell Res Ther. 2022;13(1):55.

    Google Scholar 

  • Huang Y, Li X, Zhu T, Lin J, Tao G. Efficacy and safety of ropivacaine addition to intrathecal morphine for pain management in intractable cancer. Mediators Inflamm. 2015;2015:439014.

    Google Scholar 

  • Stearns LM, Abd-Elsayed A, Perruchoud C, Spencer R, Hammond K, Stromberg K, et al. Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesth Analg. 2020;130(2):289–97.

    Google Scholar 

  • Smyth C, Ahmadzai N, Wentzell J, Pardoe A, Tse A, Nguyen T, et al. Intrathecal analgesia for chronic refractory pain: current and future prospects. Drugs. 2015;75(17):1957–80.

    Google Scholar 

  • Akhlaghpasand M, Tavanaei R, Hosseinpoor M, et al. Effects of combined intrathecal mesenchymal stem cells and Schwann cells transplantation on neuropathic pain in complete spinal cord injury: A phase II randomized Active-Controlled trial. Cell Transpl. 2025;34:9636897241298128.

    Google Scholar 

  • Boukelmoune N, Laumet G, Tang Y, Ma J, Mahant I, Nijboer C, et al. Nasal administration of mesenchymal stem cells reverses chemotherapy-induced peripheral neuropathy in mice. Brain Behav Immun. 2021;93:43–54.

    Google Scholar 

  • Tian L, Shang Y, Chen R, Bai R, Chen C, Inthavong K, et al. Correlation of regional deposition dosage for inhaled nanoparticles in human and rat olfactory. Part Fibre Toxicol. 2019;16:6.

    Google Scholar 

  • Chen G, Park CK, Xie RG, Ji RR. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion. J Clin Invest. 2015;125(8):3226–40.

    Google Scholar 

  • Shiue SJ, Rau RH, Shiue HS, Hung YW, Li ZX, Yang KD, et al. Mesenchymal stem cell exosomes as a cell-free therapy for nerve injury–induced pain in rats. Pain. 2019;160(1):210–23.

    Google Scholar 

  • Xu Y, Tian NX, Bai QY, Chen Q, Sun XH, Wang Y. Gait assessment of pain and analgesics: comparison of the DigiGait™ and CatWalk™ gait imaging systems. Neurosci Bull. 2019;35(3):401–18.

    Google Scholar 

  • Ge MM, Li DY, Wang L, Zhang LQ, Liu DQ, Tian YK, et al. Naringenin promoted spinal microglia M2 polarization in rat model of cancer-induced bone pain via regulating AMPK/PGC-1α signaling axis. Biomed Pharmacother. 2022;149:112912.

    Google Scholar 

  • Hu XM, Yang W, Du LX, Cui WQ, Mi WL, Mao-Ying QL, et al. Vascular endothelial growth factor A signaling promotes spinal central sensitization and pain-related behaviors in female rats with bone cancer. Anesthesiology. 2019;131(5):1125–47.

    Google Scholar 

  • Liu H, Lv X, Zhao X, Yi L, Lv N, Xu W, et al. Spinal astrocyte-derived interleukin-17A promotes pain hypersensitivity in bone cancer mice. Acta Pharm Sin B. 2024;14(12):5249–66.

    Google Scholar 

  • Cao TT, Chen H, Pang M, Xu SS, Wen HQ, Liu B, et al. Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury. Neural Regen Res. 2022;17(8):1785.

    Google Scholar 

  • Yang Y, Cao TT, Tian ZM, Gao H, Wen HQ, Pang M, et al. Subarachnoid transplantation of human umbilical cord mesenchymal stem cell in rodent model with subacute incomplete spinal cord injury: preclinical safety and efficacy study. Exp Cell Res. 2020;395(2):112184.

    Google Scholar 

  • Echeverry S, Shi XQ, Rivest S, Zhang J. Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. J Neurosci. 2011;31(30):10819–28.

    Google Scholar 

  • Lu P, Gonzales C, Chen Y, Adedoyin A, Hummel M, Kennedy JD, et al. CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system. Life Sci. 2009;85(11–12):450–6.

    Google Scholar 

  • Wang X, Wang Q, Meng L, Tian R, Guo H, Tan Z, et al. Biodistribution-based administration of cGMP-compliant human umbilical cord mesenchymal stem cells affects the therapeutic effect of wound healing. Stem Cell Rev Rep. 2024;20(1):329–46.

    Google Scholar 

  • Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

    Google Scholar 

  • Zhang M, Ni Z, Ma J, Liu A, Liu Y, Lou Q, et al. A neural circuit for sex-dependent conditioned pain hypersensitivity in mice. Nat Commun. 2025;16(1):3639.

    Google Scholar 

  • Fan CY, McAllister BB, Stokes-Heck S, Harding EK, de Pereira Vasconcelos A, Mah LK, et al. Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain. Neuron. 2025;113(6):896-911.e9.

    Google Scholar 

  • Grundtner S, Sondermann JR, Xian F, Malzl D, Segelcke D, Pogatzki-Zahn EM, et al. Deep proteomics and network pharmacology reveal sex- and age-shared neuropathic pain signatures in mouse dorsal root ganglia. Pharmacol Res. 2025;211:107552.

    Google Scholar 

  • Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48(23):6876–81.

    Google Scholar 

  • Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat. 1994;32(1):73–84.

    Google Scholar 

  • Shih LY, Shih HN, Chen TH. Bone resorption activity of osteolytic metastatic lung and breast cancers. J Orthop Res. 2004;22(6):1161–7.

    Google Scholar 

  • Mao-Ying QL, Wang XW, Yang CJ, Li X, Mi WL, Wu GC, et al. Robust spinal neuroinflammation mediates mechanical allodynia in Walker 256 induced bone cancer rats. Mol Brain. 2012;5:16.

    Google Scholar 

  • Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, et al. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun. 2006;345(4):1292–8.

    Google Scholar 

Continue Reading

  • China’s EV strategy: winning hearts (and markets) in the Global South – Medium

    1. China’s EV strategy: winning hearts (and markets) in the Global South  Medium
    2. Latin America EV Sales Report: 6% Market Share Reached in Q3 Thanks to 55% Growth YoY  CleanTechnica
    3. Uruguay Switched to EVs When Gas Hit $7, Would Americans Do the Same?  Autoblog
    4. Electric vehicle sales are booming in South America — without Tesla  Reuters
    5. Tesla Fails to Join the EV Carnival as Chinese Rivals Grab South American Share  TipRanks

    Continue Reading

  • Why Analysts See SAP’s Narrative Shifting Amid New Risks and Growth Drivers

    Why Analysts See SAP’s Narrative Shifting Amid New Risks and Growth Drivers

    SAP’s price target has seen a minor downward adjustment, with the fair value decreasing slightly from €288.67 to €287.58 and the discount rate lowered from 6.36% to 6.32%. This subtle change reflects updates in analyst expectations, which have been shaped by evolving revenue forecasts and adjustments to underlying assumptions. Readers interested in how these shifting outlooks could impact SAP’s future performance should stay tuned for insights on tracking the ongoing narrative and its implications.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value SAP.

    Analyst sentiment on SAP has been dynamic in recent months, reflecting both confidence in the company’s long-term potential and ongoing scrutiny of its near-term challenges. Below is a synthesis of the key takeaways from recent research notes.

    🐂 Bullish Takeaways

    • JPMorgan’s Toby Ogg raised his price target to EUR 310 from EUR 290, reaffirming an Overweight rating and highlighting continued confidence in SAP’s growth outlook.

    • Barclays increased its price target to $348 from $322, maintaining an Overweight rating. While acknowledging some softness in cloud guidance and software declines, Barclays noted more positive sentiment around the macro environment and a robust Q4 pipeline. This suggests improving prospects for revenue acceleration next year.

    • Oddo BHF upgraded SAP to Outperform from Neutral and slightly bumped its price target to EUR 284. Oddo BHF described the recent share pullback as a buying opportunity and credited SAP’s earnings resilience even in a weaker macroeconomic backdrop.

    • Jefferies reiterated its Buy rating and a EUR 290 price target, highlighting SAP’s “multiple levers of growth and sensible strategic choices to sustain durable growth.” Jefferies expects the stock to rebound following recent weakness, pointing to management’s transparent approach and growth execution.

    🐻 Bearish Takeaways

    • BMO Capital took a more cautious view, lowering its price target to $320 from $330 while keeping an Outperform rating. While recognizing solid Q3 results, BMO noted some disappointment around the Q4 guidance and flagged uncertainties about near-term growth momentum.

    • Some analysts expressed concerns around valuation, with suggestions that much of the upside may already be reflected in SAP’s current share price. Ongoing risks tied to macroeconomic conditions and the pace of cloud revenue conversion were also noted.

    Together, these perspectives highlight that while many on Wall Street remain positively disposed towards SAP’s strategic direction and execution capabilities, certain reservations persist, particularly regarding near-term revenue dynamics and valuation levels. Investors should continue to monitor how well SAP balances its growth ambitions with transparency and cost discipline to deliver on the expectations set by recent analyst commentary.

    Continue Reading

  • How the Story Around Federated Hermes Is Evolving Amid Analyst Shifts and New Growth Drivers

    How the Story Around Federated Hermes Is Evolving Amid Analyst Shifts and New Growth Drivers

    Federated Hermes’ fair value estimate has experienced a modest uptick, with the price target rising slightly from $52.29 to $52.43 following the latest round of analyst updates. This change comes as market experts weigh the company’s robust quarterly earnings and ongoing industry momentum, while also considering cautious views about the stock’s current valuation. Stay tuned to see how investors can track and respond to future shifts in sentiment and price targets as this narrative continues to evolve.

    Stay updated as the Fair Value for Federated Hermes shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Federated Hermes.

    Recent analyst commentary on Federated Hermes reflects a mixture of optimism and ongoing caution. Several notable firms have updated their outlook following the company’s latest earnings and industry developments, weighing strong performance against considerations of current valuation.

    🐂 Bullish Takeaways:

    • Evercore ISI raised its price target for Federated Hermes to $55 from $48 and maintained an Outperform rating. The firm highlighted sustained industry organic growth for a fourth consecutive month, as well as a positive close to the summer for both stocks and bonds. This signals sector momentum and improved asset flows.

    • JPMorgan increased its price target to $56 from $55 while keeping a Neutral rating. The firm’s analysts cited the company’s Q3 earnings beat as a key driver for the upward revision and noted that execution on earnings continues to impress.

    • Analysts overall pointed to robust quarterly execution and industry-wide positive trends as drivers behind recent price target increases.

    🐻 Bearish Takeaways:

    • TD Cowen lifted its price target to $53 from $51 and maintained a Hold rating. The firm emphasized that, despite recent model updates, there is not enough residual value at current trading levels to prompt a more aggressive stance. TD Cowen points to valuation as a near-term risk, suggesting that much of the upside appears to be priced in.

    • Cautious sentiment persists among some analysts who, while recognizing operational momentum, remain hesitant due to concerns over the stock’s valuation and limited further upside.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    NYSE:FHI Community Fair Values as at Nov 2025
    • Federated Hermes has launched the Enhanced Income ETF (CBOE: PAYR), aiming to provide steady monthly income to investors by blending high-dividend stock investments with options strategies. This new ETF is designed specifically for those seeking regular cash flow from their portfolios.

    • The Enhanced Income ETF is managed collaboratively by the Multi-Asset Investment Team and the Strategic Value Dividend Team. Their combined expertise focuses on disciplined risk management and generating reliable income for investors.

    • As of September 30, 2025, Federated Hermes oversees more than $1.2 billion in ETF assets, reflecting a growing suite of actively managed ETFs tailored to diverse investment goals.

    • The company has also introduced the MDT Market Neutral ETF, which focuses on long-term capital appreciation with strategies designed to limit exposure to overall market risk. This fund is managed by the Federated Hermes MDT Advisers team, which has an established history in market neutral investing.

    Continue Reading

  • Why The Narrative Around CIBC Is Shifting Following Fresh Analyst Updates and Market Signals

    Why The Narrative Around CIBC Is Shifting Following Fresh Analyst Updates and Market Signals

    Canadian Imperial Bank of Commerce has seen its Fair Value Estimate climb slightly, rising from CA$110.01 to CA$112.88 per share as analyst sentiment shifts more positively. This change reflects a mix of renewed optimism, with robust quarterly results and expanding net interest margins driving higher price targets. At the same time, some caution persists among analysts. Stay tuned to discover how you can follow these evolving perspectives and stay ahead of important updates shaping the bank’s future outlook.

    Stay updated as the Fair Value for Canadian Imperial Bank of Commerce shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Canadian Imperial Bank of Commerce.

    Recent analyst commentary on Canadian Imperial Bank of Commerce (CIBC) continues to reflect a dynamic mix of optimism and ongoing caution. Multiple firms have updated their outlooks, adjusting price targets in response to the bank’s latest quarterly performance and evolving sector conditions.

    🐂 Bullish Takeaways

    • Scotiabank and RBC Capital reiterated Outperform ratings, with Scotiabank’s Mike Rizvanovic raising CIBC’s price target to C$121 from C$116. RBC Capital increased its target to C$113 from C$112, highlighting confidence in CIBC’s fundamentals and growth trajectory.

    • BMO Capital and TD Cowen also issued price target hikes to C$112 and C$117 respectively, maintaining Outperform and Buy ratings. These actions indicate momentum in core performance and a favorable view of the latest quarter.

    • BofA raised its price target to C$114 from C$110, citing Q3 core EPS that exceeded both firm and consensus expectations, driven by robust pre-tax pre-provision income. The firm anticipates net interest margin expansion in both U.S. and Canadian segments to continue supporting earnings power.

    • Strong growth in Canadian Personal and Business banking, ongoing net interest margin expansion, and resilient capital markets activity were consistently recognized as key drivers for upgraded valuations.

    • Analysts highlighted CIBC’s ability to execute on cost control and deliver above-consensus earnings. Canaccord noted net interest margin improvement and momentum as especially positive for near-term performance.

    🐻 Bearish Takeaways

    • Canaccord maintained a Hold rating despite multiple price target increases, most recently raising its target to C$117 from C$111. This reflects a more cautious stance linked to valuation considerations and upside that may already be reflected in the share price.

    • Barclays lifted its price target to C$106 from C$96 but kept an Underweight rating. This signals ongoing reservations regarding the bank’s valuation and the potential for near-term risks, even as results exceeded consensus expectations.

    • Some analysts continue to flag concerns around the sustainability of earnings growth and pressures from broader economic uncertainty. This has led to a divergence in overall sentiment despite solid recent quarters.

    Continue Reading